Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Fineline Cube Jun 29, 2026
Company Drug

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Fineline Cube Jun 29, 2026
Company Drug

RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval

Fineline Cube Aug 1, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...

Company R&D

Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation

Fineline Cube Aug 1, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with...

Company Drug

Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment

Fineline Cube Aug 1, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...

Company Drug

Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment

Fineline Cube Aug 1, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...

Company Drug

Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study

Fineline Cube Aug 1, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...

Company Drug

Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China

Fineline Cube Aug 1, 2023

China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...

Company

WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023

Fineline Cube Aug 1, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...

Company

HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023

Fineline Cube Aug 1, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...

Policy / Regulatory

Shanghai HSA Unveils Measures to Boost Access to Innovative Drugs and Devices

Fineline Cube Aug 1, 2023

The Healthcare Security Administration (HSA) in Shanghai has recently released a set of Measures aimed...

Company

Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results

Fineline Cube Jul 31, 2023

Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...

Company Medical Device

MicroPort MedBot’s SkyWalker Orthopedic Surgery Robot Gains TGA Approval in Australia

Fineline Cube Jul 31, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

CDE Releases Draft Guidelines for Clinical Pharmacology Research of Chemical Modified Drugs

Fineline Cube Jul 31, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Pharmacological Research...

Company Deals

Baidu Health Partners with GSK for Shingles Disease Education Programs in China

Fineline Cube Jul 31, 2023

China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with...

Company Drug

Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density

Fineline Cube Jul 31, 2023

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors

Fineline Cube Jul 31, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...

Company Deals

Mabwell Secures Licensing Deal with Morocco’s Sothema for Biosimilar Humira

Fineline Cube Jul 31, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a significant licensing and commercialization...

Company Drug

Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...

Company Drug

Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA

Fineline Cube Jul 31, 2023

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...

Company Deals

Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol

Fineline Cube Jul 31, 2023

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...

Company Deals

AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer

Fineline Cube Jul 31, 2023

AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...

Posts pagination

1 … 517 518 519 … 688

Recent updates

  • AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
  • Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval
  • Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use
  • Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax
  • J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older

Company Drug

Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval

Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.